Incidence of local recurrence in relation to radiotherapy and trastuzumab in early Her2 positive breast cancer

被引：0
|
作者：
Traa, F. [1 ]
Vane, M. [1 ]
Van Roozendaal, L. [2 ]
Heuts, E. [1 ]
Siesling, S. [3 ]
Moossdorff, M. [2 ]
Smidt, M. [1 ]
机构：
[1] Maastricht Univ, Med Ctr, Surg, Maastricht, Netherlands
[2] Zuyderland Med Ctr, Surg, Heerlen, Netherlands
[3] Univ Twente, MIRA Inst Biomed Technol & Tech Med, Hlth Technol & Serv Res, Enschede, Netherlands
来源：
EUROPEAN JOURNAL OF CANCER | 2018年 / 92卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
368 (PB-16
引用
收藏
页码：S104 / S105
页数：2
相关论文
共 50 条
  • [41] Role of trastuzumab in patients with brain metastases from Her2 positive breast cancer
    Nilufer Bulut
    Hakan Harputluoglu
    Omer Dizdar
    Kadri Altundag
    Journal of Neuro-Oncology, 2008, 86 : 241 - 241
  • [42] Modelling hypersensitivity to trastuzumab defines biomarkers of response in HER2 positive breast cancer
    Diaz-Gil, Laura
    Braso-Maristany, Fara
    Locatelli, Claudriana
    Centa, Ariana
    Gyorffy, Balasz
    Ocana, Alberto
    Prat, Aleix
    Pandiella, Atanasio
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2021, 40 (01)
  • [43] Long-term trastuzumab treatment in HER2 positive metastatic breast cancer
    Calamac, M.
    Minic, I.
    Tomasevic, Z.
    Oblakovic-Babic, J.
    Serovic, K.
    Djurmez, O.
    Dimitrijevic, M.
    Bozovic-Spasojevic, I.
    BREAST, 2021, 56 : S82 - S83
  • [44] Trastuzumab for patients with HER2 positive breast cancer: Delivery, duration and combination therapies
    Pinto, Ana Catarina
    Ades, Felipe
    de Azambuja, Evandro
    Piccart-Gebhart, Martine
    BREAST, 2013, 22 : S152 - S155
  • [45] ANALYSIS OF MINIMIZATION OF COSTS OF THE USE OF SUBSTITUTE TRASTUZUMAB FOR INTRAVENOUS TRASTUZUMAB IN THE TREATMENT OF EARLY BREAST CANCER IN WOMEN WITH HER2 POSITIVE FOR VENEZUELA
    Romero, M.
    Acero, G.
    Huerfano, L. M.
    VALUE IN HEALTH, 2015, 18 (07) : A823 - A823
  • [46] Risk factors for brain metastasis as a first site of disease recurrence in patients with HER2 positive early stage breast cancer treated with adjuvant trastuzumab
    Tonyali, Onder
    Coskun, Ugur
    Yuksel, Sinemis
    Inanc, Mevlude
    Bal, Oznur
    Akman, Tulay
    Yazilitas, Dogan
    Ulas, Arife
    Kucukoner, Mehmet
    Aksoy, Asude
    Demirci, Umut
    Uysal, Mukremin
    Tanriverdi, Ozgur
    Gunaydin, Yusuf
    Sumbul, Ahmet Taner
    Yildiz, Ramazan
    Karaca, Halit
    Oksuzoglu, Berna
    Ciltas, Aydin
    Buyukberber, Suleyman
    Benekli, Mustafa
    BREAST, 2016, 25 : 22 - 26
  • [47] Correlation of trastuzumab treatment benefit with quantitative HER2 expression levels in HER2 positive metastatic breast cancer.
    Bachmeier, Beatrice
    Sperinde, Jeff
    Weidler, Jodi Marie
    Lie, Yolanda
    Chenna, Ahmed
    Winslow, John
    Engel, Jutta
    Schubert-Fritschle, Gabriele
    Sommerhoff, Christian
    Petropoulos, Christos J.
    Bates, Michael Patrick
    Huang, Weidong
    Nerlich, Andreas
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [48] Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer
    Douchet, G.
    Richard, Sandrine
    ONCOLOGIE, 2018, 20 (01) : 43 - 44
  • [49] Trastuzumab and Vinorelbine in Early Stages of HER2-Positive Breast Cancer
    Ferrario, C.
    Wong, A.
    Gao, T.
    Bouganim, N.
    Aloyz, R.
    Panasci, L. C.
    JOURNAL OF CHEMOTHERAPY, 2011, 23 (01) : 32 - 35
  • [50] Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
    von Minckwitz, Gunter
    Procter, Marion
    de Azambuja, Evandro
    Zardavas, Dimitrios
    Benyunes, Mark
    Viale, Giuseppe
    Suter, Thomas
    Arahmani, Amal
    Rouchet, Nathalie
    Clark, Emma
    Knott, Adam
    Lang, Istvan
    Levy, Christelle
    Yardley, Denise A.
    Bines, Jose
    Gelber, Richard D.
    Piccart, Martine
    Baselga, Jose
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (02): : 122 - 131
12345